development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240–627–3705 or *Chris.Kornak@nih.gov.* Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use

Description of Technology: National Institute of Allergy and Infectious Diseases (NIAID), International AIDS Vaccine Initiative (IAVI), Emergent, and Scripps have developed two recombinant adenovirus type 4 (Ad4) vector-based vaccine candidates. These replicating Ad4 vector-based candidates have shown improved activity against tier 2 HIV–1 isolates in experimental animals. Tier 2 isolates are among the most prevalent in infected populations. The two candidates, Ad4-Env150KN and Ad4-Env145NFL, incorporate novel design features based on Ad4-EnvC150 (1086c). Specifically, the truncation of the cytoplasmic tail of Env increases cell surface expression and has resulted in improved antigenicity from both candidates.

Additionally, the upper respiratory tract administration offers a way to bypass pre-existing Ad4 immunity in most people. Furthermore, unlike non-replicating vectors, these vaccines may evoke a durable immune response.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications

- Prophylaxis against HIV–1.

Competitive Advantages

- Replicating vector may invoke durable immunity against HIV–1.
- Potential for prophylactic use in high-risk populations.
- Upper-respiratory (intranasal) administration will bypass pre-existing Ad4 immunity in most people.

Development Stage

- Phase 1 Clinical Trial (NCT03878121).

Inventors: Mark Connors (NIAID), Jeff Alexander (Emergent), Lo Vang (Emergent), Richard Wyatt (Scripps and IAVI), and Javier Guenaga (IAVI).

Publications: Alexander J., Mendy J., Vang L., Avanzini J.B., Garduno F., et al. (2013) Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV–1 Envelope 1086 Clade C. PLOS ONE 8(12): e82380. *https://doi.org/10.1371/journal.pone.0082380.*

Intellectual Property: HHS Reference No. E–105–2020–0–PCT–01—PCT Application No. PCT/US21/45389 filed on 10 August 2021.

Licensing Contact: To license this technology, please contact Chris Kornak at 240–627–3705 or *Chris.Kornak@nih.gov,* and reference E–105–2020.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. In particular, NIAID would be very interested in a partnership with an entity that has a complementary HIV vaccine technology. For collaboration opportunities, please contact Chris Kornak at 240–627–3705 or *Chris.Kornak@nih.gov.*

Dated: April 25, 2022.

Surekha Vathyam,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2022–09158 Filed 4–27–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Secretary; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Interagency Pain Research Coordinating Committee.

The meeting will be open to the public via NIH Videocast *https://videocast.nih.gov/.* Individuals who plan to participate and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Interagency Pain Research Coordinating Committee.

Date: June 7, 2022.

Time: 2:00 p.m. to 5:00 p.m. Eastern Daylight Time (EDT).

Agenda: The meeting will cover committee business items and IPRCC member updates. Items discussed will include updates on pain workforce enhancement, pain research, patient engagement, and diversity efforts.

Webcast Live: https://videocast.nih.gov/.

Deadline: Submission of intent to submit written/electronic statement for comments: Tuesday, May 31st, by 5:00 p.m. EDT.

Place: National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Linda L. Porter, Ph.D., Director, Office of Pain Policy and Planning, Office of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 8A31, Bethesda, MD 20892, Phone: (301) 451–4460, Email: *Linda.Porter@nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Visit the IPRCC website for more information: *https://iprcc.nih.gov.* Agenda and any additional information for the meeting will be posted when available.

Dated: April 25, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–09140 Filed 4–27–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive, sublicensable patent license to the University of Washington, located in Seattle, State of Washington, U.S.A. in its rights to the inventions and the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

DATES: Only written comments and/or applications for a license which are

received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases (NIAID) on or before May 13, 2022 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Amy Petrik, Technology Transfer and Patent Specialist, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852–9804, phone number 240–627–3721, or *amy.petrik@nih.gov.*

SUPPLEMENTARY INFORMATION: The following and all continuing patents/patent applications thereof are the intellectual property to be licensed under the prospective agreement to the University of Washington: United States Provisional Patent Application Number 62/986,295, filed March 6, 2020, entitled ''Engineered Influenza Neuraminidase Antigens'' (HHS Reference No. E–052–2021–0–US–01) and Patent Cooperation Treaty (PCT) Patent Application Number PCT/US2021/020804, filed March 4, 2021, entitled ''Engineered Influenza Neuraminidase Antigens'' (HHS Reference No. E–052–2021–0–PCT–02).

The patent rights in these inventions have been assigned to the University of Washington and Government of the United States of America as represented by the Secretary, Department of Health & Human Services.

The prospective patent license will be for the purpose of consolidating the patent rights to the University of Washington, the co-owners of said rights, for commercial development and marketing.

Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective inter-institutional agreement may include an exclusive license for NIAID's rights in these jointly owned patent applications. It will be sublicensable, and any sublicenses granted by the University of Washington will be subject to the provisions of 37 CFR part 401 and 404.

In the subject technology, researchers at NIAID and the University of Washington engineered the neuraminidase glycoprotein from the influenza virus to improve its properties as an antigen. The patent applications claim the mutations that the researchers introduced to stabilize the neuraminidase protein in its closed conformation and use of the engineered protein in an influenza vaccine.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will include a share of the royalties from the licensing of this invention back to the NIAID, and may be granted unless within fifteen (15) days from the date of this published notice, NIAID receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

Complete license applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under *the Freedom of Information Act,* 5 U.S.C. 552.

Dated: April 25, 2022.

Surekha Vathyam,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2022–09156 Filed 4–27–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Immigration and Customs Enforcement

[OMB Control Number 1653–0037]

Agency Information Collection Activities; Revision of a Currently Approved Collection: Notice to Student or Exchange Visitor

AGENCY: U.S. Immigration and Customs Enforcement, Department of Homeland Security.

ACTION: 60-Day notice.

SUMMARY: The Department of Homeland Security (DHS), U.S. Immigration and Customs Enforcement (ICE) invites the general public and other Federal agencies to comment on this proposed revision of a currently approved collection of information. In accordance with the Paperwork Reduction Act (PRA) of 1995, this information collection notice is published in the **Federal Register** to obtain comments regarding the nature of the information collection, the categories of respondents, the estimated burden (*i.e.,* the time, effort, and resources used by the respondents to respond), the estimated cost to the respondent, and the actual information collection instruments.

DATES: Comments are encouraged and will be accepted until June 27, 2022.

ADDRESSES: All submissions received must include the OMB Control Number 1653–0037 in the body of the correspondence, the agency name and Docket ID ICEB–2009–0004. All comments received will be posted without change to *https://www.regulations.gov,* including any personal information provided.

(1) *Online.* Submit comments via the Federal eRulemaking Portal website at *https://www.regulations.gov* under e-Docket ID number ICEB–2009–0004.

FOR FURTHER INFORMATION CONTACT: If you have questions related to this collection, call or email Sharon Snyder, Unit Chief, Policy and Response Unit, Student and Exchange Visitor Program email: *sevp@ice.dhs.gov,* telephone: 703–603–3400. This is not a toll-free number. Program information can be found at *https://www.ice.gov/sevis/.*

SUPPLEMENTARY INFORMATION:

Comment

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.